Wide Ranks

MNKD

MannKind Corporation

6.61

Top Statistics
Market Cap 1 B Forward PE 40.06 Revenue Growth 36.70 %
Current Ratio 4.54 Trailing PE 82.62 Earnings Growth 524.60 %
Profit Margins 8.07 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 30.02 Enterprise / Revenue 7.16 Price To Sales Trailing12 Months 6.82
Profitability
Profit Margins 8.07 % Operating Margins 21.71 %
Balance Sheet
Total Cash 257 M Total Cash Per Share 0.9340 Total Debt 346 M
Total Debt To Equity Current Ratio 4.54 Book Value Per Share -0.7610
All Measures
Short Ratio 1589.00 % Message Board Id finmb_9282918 Shares Short Prior Month 42 M
City Danbury Uuid 44f4c2b0-ea57-32ef-9865-46daf7cd45e6 Previous Close 6.58
First Trade Date Epoch Utc 1 B Book Value -0.7610 Beta 1.30
Total Debt 346 M Volume 3 M Last Split Date 1 B
Fifty Two Week Low 3.17 Total Cash Per Share 0.9340 Total Revenue 267 M
Shares Short Previous Month Date 1 B Target Median Price 9.00 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Operating Margins 21.71 %
Target Mean Price 9.25 Net Income To Common 21 M Short Percent Of Float 0.1543
Implied Shares Outstanding 275 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 3 M Average Volume10days 3 M Total Cash 257 M
Next Fiscal Year End 1 B Revenue Per Share 0.9820 Held Percent Insiders 0.0183
Ebitda Margins 23.83 % Trailing PE 82.62 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 6.58 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 6.71 Open 6.55
Free Cashflow 30 M State CT Dividend Yield 0.00 %
Return On Assets 0.0912 Time Zone Short Name EST Trailing Eps 0.0800
Day Low 6.40 Address1 1 Casper Street Shares Outstanding 275 M
Price Hint 2 Target High Price 12.00 Website https://www.mannkindcorp.com
52 Week Change 0.8260 Average Volume 2 M Earnings Quarterly Growth 571.10 %
Forward Eps 0.1700 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 383.90 % Last Split Factor 1:5 Regular Market Day High 6.67
Is_sp_500 False Profit Margins 8.07 % Fifty Two Week High 7.63
Day High 6.67 Shares Short 42 M Regular Market Open 6.55
Industry Key biotechnology Earnings Growth 524.60 % Enterprise To Revenue 7.16
Revenue Growth 36.70 % Shares Percent Shares Out 0.1524 Operating Cashflow 41 M
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip 06810 Quote Type EQUITY
Industry Biotechnology Long Name MannKind Corporation Regular Market Day Low 6.40
Held Percent Institutions 0.5664 Current Price 6.61 Enterprise To Ebitda 30.02
Financial Currency USD Current Ratio 4.54 Gross Margins 71.91 %
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 269 M Two Hundred Day Average 5.36 Ir Website http://www.mannkindcorp.com/investors-mannkind.aspx
Enterprise Value 1 B Price To Sales Trailing12 Months 6.82 Forward PE 40.06
Regular Market Volume 3 M Ebitda 63 M Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.

It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.

Further, the company has supply and distribution agreement with Biomm S.

A.

for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd.

for the marketing and distribution of Afrezza in India.

MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.